3.3 Eligibility Verification and Trial Designs

Eligibility Verification and Trial Designs

"Protocol creep" is the informal, gradual erosion of baseline eligibility standards by site personnel. Over time, coordinators and investigators face recruitment pressure and begin rationalizing borderline eligibility failures (e.g., enrolling a patient with diastolic blood pressure of $92\text{ mmHg}$ when the protocol cutoff is strictly $<90\text{ mmHg}$, or accepting lab values collected outside protocol-stipulated screening windows).

CRA Detection Techniques:

• Verify source laboratory and diagnostic reports directly from central and local laboratories rather than relying on transcribed values on the eCRF.
• Check timestamps: Ensure all baseline laboratory draws, imaging scans, and washouts were completed within the exact screening window specified in the protocol.
• Audit the Screening Log: Check every screen failure.

If a site reports zero screen failures across dozens of screened subjects, investigate whether the site is improperly enrolling borderline candidates or failing to log failed screenings.

Immediate Actions upon Discovering an Ineligible Enrolled Subject

1. Assess Immediate Subject Safety: Determine whether exposure to the investigational product creates acute health risks.
2. Notify the Principal Investigator: Highlight the exact protocol violation and document the discussion.
3. Alert the Sponsor Medical Monitor: Immediately report the deviation to the sponsor's clinical team and medical monitor.
4. Evaluate Withdrawal Criteria: Consult protocol stopping rules to confirm if the subject must be discontinued from IP dosing immediately.
5. Document the Major Deviation: File a formal protocol deviation report in the eCRF system and the Investigator Site File (ISF).

Study Designs, Randomization & Bias Control Strategies

Selecting an appropriate study architecture requires balancing statistical efficiency, patient safety, disease natural history, and operational feasibility. For a Clinical Research Associate, understanding the structural mechanics of clinical study designs and their built-in bias defenses is crucial for auditing randomization compliance, safeguarding masking, and monitoring emergency unblinding events.

Clinical Trial Design Architectures

Every clinical trial implements a specific structural design that dictates how subjects are exposed to investigational and control interventions over time.

Parallel Group Design

The parallel group design is the most common and robust architecture for confirmatory Phase III trials. Subjects are randomized to one of two or more distinct arms (e.g., Investigational Drug vs. Active Comparator vs. Placebo) and remain on their assigned treatment throughout the entire observation period.

• Advantages: Clean, straightforward statistical analysis; no risk of carryover effects; applicable to many acute diseases (e.g., myocardial infarction, sepsis), progressive conditions (e.g., oncology), and chronic conditions.
• Disadvantages: High inter-individual variability between subjects across arms, requiring relatively large sample sizes to achieve adequate statistical power.

Crossover Design

In a crossover design, each participant receives two or more treatments in sequential order separated by an intervening washout interval. In the classic $2 \times 2$ design, subjects are randomized to Sequence 1 (Treatment A followed by Treatment B) or Sequence 2 (Treatment B followed by Treatment A).

• Within-Subject Comparisons: Because each participant serves as their own control, between-participant variability can be reduced from the treatment comparison. This dramatically reduces the required sample size depending on within-participant variability and the design.
• Essential Prerequisites: Crossover designs are generally suited to stable conditions with constant baseline symptoms (e.g., chronic stable angina, mild hypertension, asthma). They are often unsuitable when disease progression or irreversible treatment effects undermine within-participant comparisons.
• The Washout Period: The interval between treatment periods must be long enough to allow all residual drug and active metabolites to clear from the body as justified in the protocol, considering elimination and persistence of biological effects and for all biological/pharmacodynamic effects to return completely to baseline.
• Carryover Effect: The persistence of treatment effects from the first period into the second period. If carryover occurs, it creates a treatment-by-period interaction that can bias the treatment comparison and must be evaluated under the analysis plan.

Factorial Design ($2 \times 2$)

A factorial design evaluates two distinct experimental interventions (e.g., Drug A and Drug B) simultaneously against control within the same patient population.

• Treatment Arms: Group 1 receives Drug A + Drug B; Group 2 receives Drug A + Placebo B; Group 3 receives Placebo A + Drug B; Group 4 receives Placebo A + Placebo B.
• Efficiency: Allows testing the efficacy of both drugs simultaneously with minimal sample size inflation, provided there is no pharmacological interaction between the two treatments. It also enables explicit statistical evaluation of synergy or antagonism.

Adaptive Trial Designs

Adaptive designs allow pre-specified, planned modifications to trial procedures (such as sample size re-estimation, dropping ineffective dosage arms, or enriching patient subsets based on biomarker expression) based on accrued interim data.

• Governance: Adaptive changes must be pre-planned in the protocol and simulation models, and implemented under prespecified methods and suitable independent/unblinded review and access safeguards to prevent premature unblinding of sponsors or investigators.

Official sources

Checked October 18, 2026: ICH E6(R3), Principles and Annex 1, ICH E9, ICH E9(R1), ICH E8(R1).